Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > TSX maintain $94,13 mean and $145 high target on CXR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by healthstock1234on Nov 16, 2015 11:09am
171 Views
Post# 24294928

RE:TSX maintain $94,13 mean and $145 high target on CXR

RE:TSX maintain $94,13 mean and $145 high target on CXR6 analysts

healthstock1234 wrote:
Target Price History
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 145.00 145.00 145.00 145.00
Low Target Price Estimate 60.00 60.00 60.00 75.00
Mean Target Price Estimate 94.13 93.75 93.75 104.50
Standard Deviation 29.22 29.14 29.14 28.20
Date of Most Recent Estimate 11/13/15 10/26/15 10/26/15 10/22/15



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities